Pain133(2007)210–220
www.elsevier.com/locate/pain
Sativex successfully treats neuropathic pain characterised
by allodynia: A randomised, double-blind,
placebo-controlled clinical trial
Turo J. Nurmikko a,*, Mick G. Serpell b, Barbara Hoggart c, Peter J. Toomey d,
Bart J. Morlion e, Derek Haines f
aDivisionofNeurologicalScience,UniversityofLiverpool,Liverpool,UnitedKingdom
bGartnavelGeneralHospital,Glasgow,UnitedKingdom
cSolihullHospital,Birmingham,UnitedKingdom
dYorkDistrictHospital,York,UnitedKingdom
eUniversityHospital,Leuven,Belgium
fCastleHillHospital,Hull,UnitedKingdom
Received11March2007;receivedinrevisedform21August2007;accepted21August2007
Abstract
Cannabinoids areknown tohave analgesicproperties. We evaluatedthe effectoforo-mucosal sativex,(THC:CBD),anendo-
cannabinoid system modulator, on pain and allodynia, in 125 patients with neuropathic pain of peripheral origin in a five-week,
randomised,double-blind,placebo-controlled,paralleldesigntrial.Patientsremainedontheirexistingstableanalgesia.Aself-titrat-
ingregimenwasusedtooptimisedrugadministration.Sixty-threepatientswererandomisedtoreceivesativexand62placebo.The
mean reduction in pain intensity scores (primary outcome measure) was greater in patients receiving sativex than placebo (mean
adjustedscores(cid:2)1.48pointsvs.(cid:2)0.52pointsona0–10NumericalRatingScale(p=0.004;95%CI:(cid:2)1.59,(cid:2)0.32).Improvements
in Neuropathic Pain Scale compositescore (p=0.007),sleepNRS (p=0.001), dynamic allodynia(p=0.042),punctate allodynia
(p=0.021),PainDisabilityIndex(p=0.003)andPatient’sGlobalImpressionofChange(p<0.001)weresimilarlygreateronsat-
ivex vs. placebo. Sedative and gastrointestinal side effects were reported more commonly by patients on active medication. Of all
participants,18%onsativexand3%onplacebowithdrewduringthestudy.Anopen-labelextensionstudyshowedthattheinitial
painrelief wasmaintained withoutdose escalation ortoxicityfor 52weeks.
(cid:2)2007International Association for the Studyof Pain.PublishedbyElsevier B.V.Allrights reserved.
Keywords: Sativex;Cannabinoid;Peripheralneuropathicpain;Allodynia
1. Introduction drugs,opioidsandtopicallocalanaestheticsconstituting
the first-line therapy [2]. Despite differences in their
The treatment of chronic neuropathic pain is mainly mechanism of action, these agents appear similar in
pharmacological, with antidepressants, antiepileptic analgesic efficacy and tolerability. There is a well-recog-
nised need for better pain relief than is currently avail-
able. This study reports the effect of the administration
* Correspondingauthor.Address:PainResearchInstitute,Division of a highly standardised THC:CBD endocannabinoid
of Neurological Science, University of Liverpool Clinical Sciences system modulator, sativex (Sativex(cid:3)), on the severity
Centre,LowerLane,LiverpoolL97AL,UnitedKingdom.Tel.:+44
of painand allodynia, andassociatedsleep disturbance,
(0)1515295820;fax:+44(0)1515295821.
mentaldistressanddisabilityinpatientswithperipheral
E-mailaddress:tjn@liv.ac.uk(T.J.Nurmikko).
0304-3959/$32.00 (cid:2)2007InternationalAssociationfortheStudyofPain.PublishedbyElsevierB.V.Allrightsreserved.
doi:10.1016/j.pain.2007.08.028
T.J.Nurmikkoetal./Pain133(2007)210–220 211
neuropathic pain. Identification of cannabinoid recep- sation schedule was held by the sponsor with a copy in
tors [20] and encouraging results from preclinical and patient-specific sealedenvelopes sentto the pharmacyin each
clinical studies [15,16] and change in the political and centre. Once the patient’s eligibility was confirmed, they were
scientificsceneinsomecountries,notablyCanada,have assigned to the next sequential randomisation number within
each centre. The placebo medication was identical in compo-
led to revived interest in cannabinoids as a therapeutic
sition,appearance,odourandtastewiththestudymedication
modality. Two controlled trials on central pain associ-
but without cannabis extract. That the smell and taste of the
ated with MS found short-term efficacy from them
cannabinoid preparation might lead to unblinding was
[26,30], whereas two other studies in which pain was
averted by disguising them with addition of peppermint oil
not a primary outcome measure gave conflicting results
to both preparations. All medication was provided in identi-
[33,40].Neuropathicpainofperipheralormixedperiph- cal amber vials, packaged and labelled by the sponsor.
eral and central origin was reported to respond to aju-
lemic acid, sativex or smoked cannabis; however, 2.2. Studypatients
treatment arms in these studies were short, between 5
and 14 days [1,6,19]. Patientshadtohaveacurrenthistoryofunilateralperiph-
Sativex is derived from extracts of selected strains of eral neuropathic pain and allodynia. Further enrolment crite-
ria are shown in Table 1. Concomitant analgesia was
cannabis plants (Cannabis sativa) which produce high
maintained at a stable dosage regimen for the duration of
and reproducible yields of the principal active cannabi-
the study. The decision to recruit was based on the patient’s
noids, delta-9-tetrahydrocannabinol (THC) and canna-
history. No tests for drugs of abuse potential were carried
bidiol (CBD). It is administered as a spray for sub-
out. Ethical approval was granted by the Local Ethics Com-
lingual and oro-pharyngeal administration. Each
mittees of the participating centres. In one centre the
100ll spray delivers 2.7mg of THC and 2.5mg of approval was conditional on patients not driving during the
CBD. trial.
Cannabinoids are thought to work via two types of
receptors, CB1 and CB2. CB1 is widely distributed in 2.3. Studymedicationandprocedures
the peripheral and central nervous system, acting as a
presynaptic modulator of neurotransmitter release. Initial dosing was under clinical supervision at the study
site. A pre-dose 100mm ‘‘Intoxication’’ (0= no intoxication
The main target for the effects of THC, CB1, occurs
and 100=extreme intoxication) Visual Analogue Scale
at many sites critical for nociception. CB2 is also acti-
(VAS) was obtained and vital signs were checked. A maxi-
vated by THC but in normal circumstances is found in
mum of 8 sprays were administered over 2h with Intoxica-
immune cells only. However, in clinical pain the role of
tion VAS and vital signs checked at regular intervals. If,
the CB2 receptor may be different because following
following any dose, patients scored higher than 25mm, or
tissue injury it is shown to be expressed in central ner- there were clinical concerns, e.g. the patients showing dys-
vous system microglia and dorsal root ganglion cells phoria or cardiovascular changes, subsequent doses were
following tissue injury [28] CBD appears to have lim- omitted [6,7].
ited affinity for either cannabinoid receptor, but in After satisfactory completion of initial dosing, patients
higher doses may potentiate the effects of THC [32] beganhomedosetitrationandwereallowedamaximumdose
and mediate non-cannabinoid effects by activating the of 8 sprays per 3-hour interval and a maximum of 48 sprays
per 24h. At the next visit (after 7–10 days) titration, compli-
TRPV1 receptor [8]. Combining the two in the same
ance and adverse events were reviewed, and patients advised
preparation is thought to lead not only to increased
on how to optimise dosing for the rest of the study period.
analgesic effect but may also result in antagonism of
Those patients who satisfactorily completed the trial were
adverse effects [27].
offeredtheopportunitytoparticipateinacommonopen-label
extension studyof sativex.
2. Methods All used and unused study medication containers were
returned at each visit to the research centre. Patients were
2.1.Study design withdrawnfromthestudyiftherewereindicationsofmisuse,
including failure to record dosage accurately. Periodic tele-
Thiswasa5-weekmulti-centre (5centresinUK, 1inBel- phone monitoringwas undertaken at pre-arranged timesdur-
gium), randomised, double-blind, placebo-controlled parallel ing home dosing to check the patient’s condition and to
group study. Patients were screened to determine eligibility answeranyqueries.Throughoutthestudy,allowableconcom-
and completed baseline diary assessments of daily pain inten- itantmedicationsortreatmentswerecontinuedtoprovideade-
sity and sleep disturbance scores in the 7–10 days prior to quate background analgesia at a constant dose. Any
first treatment assignment. After eligibility was confirmed, medication, other than the study medication taken during
patients were assigned to the next sequential randomisation the study, wasrecorded.
number within each centre. The randomisation schedule Patients kept a diary from the screening visit until end of
had a 1:1 treatment allocation ratio with randomly permuted treatment in which they recorded daily their pain and sleep
blocks stratified by centre and was generated using a com- scores (on the appropriate NRS), as well as adverse events
puterbasedpseudo-randomnumberalgorithm.Therandomi- and the numberof spraysused.
212 T.J.Nurmikkoetal./Pain133(2007)210–220
Table1
Enrolmentcriteria
Inclusioncriteria Exclusioncriteria
Unilateralperipheralneuropathicpainandallodynia Cannabinoiduse(cannabis,Marinol(cid:3)(syntheticTHC)ornabilone
(syntheticcannabinoidanalogue))atleast7daysbeforerandomisation.
Subjectswererequiredtoabstainfromuseofcannabisduringthestudy
Age18orover,maleorfemale Schizophrenia,psychosis,orothermajorpsychiatricconditionbeyond
depressionwithunderlyingcondition
Ahistoryofatleast6monthsdurationofpainduetoaclinically Concomitantseverenon-neuropathicpainorthepresenceofcancerrelated
identifiablenervelesion neuropathicpainorfromdiabetesmellitus
Demonstratemechanicalallodyniaandimpairedsensationwithin Knownhistoryofalcoholorsubstanceabuse
theterritoryofaffectednerve(s)onclinicalexamination
Patientswithcomplexregionalpainsyndrome(CRPS)were Severecardiovascularcondition,poorlycontrolledhypertension,epilepsy,
eligibleiftheyshowedevidenceofperipheralnervelesion pregnancy,lactation,significanthepaticorrenalimpairment
(diagnosedasCRPStypeII)
Abaselineseverityscoreofatleast4onthenumericalratingscale Scheduledsurgeryoranaesthesia
forspontaneouspainforatleast4of7daysinthebaselineweek
Astablemedicationregimenofanalgesicsforatleast2weeksprior Terminalillnessorsubjectsinappropriateforplacebotherapies
tostudyentry
Femalepatientsofchildbearingpotentialandmalepatientswhose Knownhypersensitivitytocannabinoids
partnerwasofchildbearingpotentialhadtoagreetouse
effectivecontraception
WillingforhisorhernametobenotifiedtotheUKHomeOffice Participationwithinatrialinthelast12weeks
2.4. Testing forallodynia surement, it was agreed that they could exercise discretion in
applying the force needed to reproduce approximately the
Testsforallodyniawerecarriedoutatbaselineandendof same pain as at baseline. The patients’ verbal pain score and
study. The investigator recorded the most painful area within pressure usedwererecorded.Each punctatepainprovocation
the affected territory. Mechanical dynamic allodynia was test wasdone onlyonce duringa single visit.
assessed by stroking the skin over the affected area five times
with a standardised brush, designed specifically for sensory 2.5. Outcome measures
testing (Senselab Brush-05, Somedic, Horby, Sweden) at
P5sintervals,andrecordingthepainseverityona0–10point Theprimaryoutcomemeasurewasachangefrombaseline
scale. All strokes were of the same length, minimum 2cm. onanumericalratingscale(NRS)ofmeanintensityofglobal
Each dynamic allodynia score was calculated as the average neuropathicpain,where0=‘‘NoPain’’and10=‘‘WorstPos-
of the fivestrokes. siblePain’’.Secondarymeasuresincludedthecompositescore
Punctate allodynia was measured using an in-house built calculated from the Neuropathic Pain Scale (NPS) [10], tests
pressure algometer comprising a strain gauge connected to a for mechanical allodynia, a four-step verbal rating scale for
metalfilamentwithadiameterof1mmandblunttipatbase- sleep disturbance (see below), the Pain Disability Index
line and end of study. The filament was manually directed (PDI) [31], the Patient Global Impression of Change (PGIC)
against the skin at an angle of 90(cid:4) and a steadily increasing ofbothpainandallodynia,andtheGeneralHealthQuestion-
pressure applied until the patient verbally indicated that they naire (GHQ-12) [5]. Possible cognitive decline was assessed
perceivedpain(punctatepressurepainthreshold).Acontralat- usingtheBriefRepeatableBatteryofNeuropsychologicaltests
eralmirrorimagesitewasusedascontroltoidentifyanysys- (BRB-N)[7].Informationregardingthefrequencyofadminis-
temic effect from the trial drugs, as well as to introduce the trationofthemedicationwasrecordedbythesubjectsintheir
method to the patient before performing the test on the allo- diary. Adverse events were collected at each clinic visit, and
dynic site. This control site was checked for evidence of local haematology, clinical chemistry and ECG monitored at the
injury, scar, rash or neurological deficit. During each session beginning and endof the study.
thenormalcontralateralsidewastestedfirst.Oncethepatient
indicated that the sensation of pressure had turned into pain, 2.6. Statistical analysis
thealgometerwasremovedandthepressurereading(ingrams)
recorded.Thesamemethodwasusedforallodynicsites. ThesamplesizecalculationwasbasedonanexpectedSDof
Inaddition, patients were askedto verbally rate the inten- 1.8forthepainintensityscore,estimatedfromseveralstudies
sityofthepainelicited,choosinganumberbetween0(nopain) onperipheralneuropathicpain.Todetectadifferencebetween
and10(mostintensepainimaginable).Theinvestigatorswere treatment groups of 1.0 on a 0–10 (11-point) NRS with 80%
awareofthepreviouspunctateallodyniathresholdandcould power and a 5% level of significance, 52 evaluable subjects
use it as guidance. Because some investigators expressed con- per group were required. A dropout rate of 15% was antici-
cern at using a rigid threshold as a targe for the second mea- pated, bringingthe totalnumber of patientsneeded to120.
T.J.Nurmikkoetal./Pain133(2007)210–220 213
The primary analysis for the primary and secondary end- 2=once, 3=twice, 4=more than twice. The scores for this
points was performed on the intention-to-treat (ITT) popula- ‘‘Sleep Disturbance NRS’’ were obtained at baseline and
tion. The neuropathic pain intensity NRS score at baseline weeklythereafteruntiltheendoftrial.Statisticalcomparisons
was defined as the mean of all diary entries from Day (cid:2)7 to wereperformedinthesamewayastheprimaryoutcomemea-
Day (cid:2)1 and, for the end of treatment score, the mean of all sure.ThePGICwascomparedbetweentreatmentsusingFish-
diary entries during the last 7 days in the study, or the last 3 er’s ExactTest.
daysintheeventofwithdrawal.TheNRSscoresweresumma-
rised by treatment group for baseline, each week and end of 3. Results
treatment. The change in NRS pain scores was compared
between treatment groups using analysis of covariance, the Atotalof141patientswereassessedforeligibility,16
modelincludingtreatmentandtrialcentreasfactorsandbase-
(11%) of whom failed to meet the eligibility criteria.
line pain severity as a covariate. From this analysis the
Sixty-three subjects were randomised to sativex and 62
adjustedtreatmentmeans,treatmentdifferenceand95%Con-
to placebo (Fig. 1). At all participating centres, the ran-
fidence Interval (95% CI) for the treatment difference were
domisationledtoacompletebalancebetweentreatment
calculated.
allocations.Baselinedemographicdetailsforbothgroups
The total scores for all questionnaires (NPS, PDI, GHQ-
12), as well as 0–10 NRS ratings of punctate and mechanical are shown in Table 2. The treatment groups were well
allodynia, were obtained at baseline and end of the 5-week matchedforage,durationofneuropathicpain,distribu-
trial. Sleep disturbance was measured by asking the subjects tion of diagnostic pain subgroups, height, weight and
to indicate the number of times they woke in previous nights for history of previous cannabis use. The diagnosis was
due to symptoms on a four category scale where 1=none, basedonexistingclinical,imagingandneurophysiological
141 entered baseline
16 excluded
4 did not meet entry criteria
3abnormallabresult
3withdrewconsent
2administrativereason
4other
125
randomised
63assignedtoreceivesativex 62assignedtoreceiveplacebo
13didnotcompletetrial 7didnotcompletethetrial
11adverseevents 5lackofefficacy
1non-compliance 2adverseevents
1lackofefficacy
50completedTrial 55completedTrial
63includedinprimaryanalysis 62includedinprimaryanalysis
47includedinperprotocolanalysis 56includedinperprotocolanalysis
15protocolviolators 5protocolviolators
1withdatacensored 1withdatacensored
Fig.1. Studyflow.
Table2 eral neuropathics were similar across the two groups
Patientcharacteristics (Table2).Thebackgrounduseofconcomitantanalgesic
Sativex Placebo medicationwashighinbothgroups.Themostfrequently
(N=63) (N=62) reported medication was opioids,being taken by 74% of
Age,yrmean(SD) 52.4(15.8) 54.3(15.2) theplacebogroupand63%ofthesativexgroup.Otherfre-
Women,N(%) 35(55.6) 39(62.9) quentlyusedbackgroundmedicationsweretricyclicanti-
White,N(%) 61(97) 60(97)
depressants,antiepilepticdrugs,andNSAIDs(Table2).
Weight,kgmean(SD)
Thirteensativexpatients(21%)failedtocompletethe
Men 79.9(16.7) 86.8(16.7)
Women 72.0(18.2) 72.7(17.3) study; 11 withdrew because of side effects, 1 due to
Durationofpain,yrmean(SD) 6.4(5.7) 6.2(6.4) patient non-compliance and one due to lack of efficacy.
Seven patients (11%) on placebo failed to complete the
Underlyingdiagnosis
Subjects(%) study,2becauseofadverseeffectsand5becauseoflack
Postherpeticneuralgia 10(16) 7(11) of effect. All randomised patients were included in the
Peripheralneuropathy 13(21) 12(19) ITT analysis. For the per-protocol (PP) analysis, there
Upperlimb 2 1
were47patientsonsativex and56onplacebo.Protocol
Lowerlimb 5 4
violations were due to failure to meet the stringent time
Face/neck/trunk 6 7
Focalnervelesion 26(41) 28(45) window set for the final visits (12 patients on sativex, 2
Upperlimb 8 7 on placebo),useofprohibitedmedication (6onsativex,
LowerLimb 10 11 twoofwhomalsofailedtomeetthefinalvisittimewin-
Face/neck/trunk 8 10
dow, and 2 on placebo) or violation of inclusion/exclu-
Radiculopathy 7(11) 6(10)
sion criteria (0onsativex,2 onplacebo).Onepatientin
CRPStypeII 7(11) 8(13)
Other 0(0) 1(2) each group had their data censored because of use of
PriorcannabisuseN(%) 13(21) 12(19) prohibited medication after Day 26.
Concomitantmedication
SubjectsN(%) 3.1. Primary outcome measure
Antiepileptic 21(33) 21(34)
Tricyclic 16(25) 21(34)
At baseline, the mean intensity of reported pain
Opioid 40(63) 46(74)
scores(SD)onNRSwasinthesevererangewithnodif-
Stronga 7(11) 8(13)
Weakb 33(52) 38(61) ferencebetweenthesativexandplacebogroups7.3(1.4)
Analgesic,non-opioid 10(16) 6(10) and7.2(1.5),respectively(Table2).Attheendoftreat-
Anti-inflammatory 10(16) 15(24) ment,thesativexgroupdemonstratedanadjustedmean
PainNRS,mean(SD) 7.3(1.4) 7.2(1.5)
changeinNRS score of(cid:2)1.48 points (a22%reduction)
NPScompositescore, 61.1(13.0) 62.4(13.7)
whilethechangefortheplacebogroupwas(cid:2)0.52points
mean(SD)
DynamicallodyniaNRS, 5.4(2.7) 5.0(3.4) (an 8% reduction) (Fig. 2). The estimated treatment
mean(SD)
PunctateallodyniaNRS, 7.3(1.8) 7.4(2.1)
mean(SD) 9 Pain
Punctateallodynia,pressureg, 68.8(47.7) 83.0(77.4)
8
mean(SD)
PainDisabilityIndex 40.9(14.7) 42.1(13.4) 7
(PDI)mean(SD)
SleepdisturbanceNRS, 3.0(0.8) 3.0(0.9) 6
mean(SD)
5
GHQ-12,mean(SD) 17.2(7.3) 17.6(6.5)
4
a Morphine,methadone,oxycodone,pethidine.
b Tramadol,codeine,dihydrocodeine,dextropropoxyphene. 3
2
1
data. Aetiologies varied from post-infectious to trau-
0
matic, vascular and idiopathic. In nearly one-half of
1 2 3 4 5
patientsthecausewasposttraumaticandinvolvedasingle
Week
nerve or nerve branch (focal nerve lesion) while in one-
fifth the lesion was at cervical, brachial or lumbosacral
plexuslevelorinvolvedseveralnerves(peripheralneurop-
athy);inthisgrouptheoriginalcausewaseitherinflam-
mation or diffuse trauma and remained frequently
unknown.Thelocationsoffocalnervelesionsandperiph-
)IC
%59(
serocS
SRN
niaP
naeM
detsujdA
214 T.J.Nurmikkoetal./Pain133(2007)210–220
*
** **
**
Sativex
* P<0.05
**P<0.01 Placebo
//
Baseline End of Treatment
Fig.2. ReductionofglobalneuropathicpainNRSscoresinthetwo
groups during the trial. First-week: home-titration; subsequent four
weeks:maintenancetherapy.Weeklymeanpainscoreswereobtained
frompaindiaries.End-pointscoreswereobtainedfromdiaryentries
duringthelast7days,orlast3daysincaseofwithdrawal,fortheITT
analysis.Errorbarsrepresent95%confidenceintervals.
difference of (cid:2)0.96 points was statistically significant in 4
Sleep Disturbance
favour of sativex (p=0.004; 95% CI: (cid:2)1.59, (cid:2)0.32).
Theimprovementinpainoverplacebowasevidentfrom
the second week after self-titration and was maintained
until the end of the study (Fig. 2). On sativex, 26% of 3
patients had at least a 30% reduction in pain score and
20% of patients had at least a 50% reduction in pain
score, compared with 15% and 8% of patients on pla-
cebo; the NNT (50%) and NNT (30%) calculated from 2
these figures were 8.5 and 8.6, respectively. Analysis of
the PP population also showed a significant treatment
difference of (cid:2)1.42 points in favour of sativex
(p<0.001; 95% CI: (cid:2)2.10, (cid:2)0.74). 1
1 2 3 4 5
3.2. Secondary outcome measures Week
All questionnaire-based measures of pain and pain-
related co-morbidity improved significantly more in
patients randomised to sativex than placebo (Table 3). (mean (SD) difference between the contralateral site
NPScompositescoreinthesativexgroupdecreasedsignif- and allodynic site: 127 (78)g). The severity of the allo-
icantlymorethanintheplacebogroup.Sleepdisturbance dynia within the affected area was comparable between
alsodecreasedearlyonandimprovementwasmaintained both sativex and placebo groups for pressure needed
untiltheendofthestudy(Fig.3).Ofthesevenfunctional to elicit pain (68.8 (47.7)g vs. 83.0 (77.4)g) and for
areas assessed in the PDI, only sexual activity failed to the level of pain generated by the stimulus itself (7.3
showasubstantialimprovementonsativex(Table3). (1.7)vs.7.4(2.1)).Attheendofstudy,therewasnoevi-
dence of a change in the punctate pain threshold at the
3.3. Allodynia contralateral control site, irrespective of whether the
patientswereonsativexorplacebo(treatmentdifference
3.3.1. Dynamic mechanical allodynia 11.1g in favour of placebo; p=0.3). At the allodynic
All patientsrecruitedinto the study showed dynamic site, the placebo group reported unchanged punctate
allodynia. There was no difference in detected mean pain pressure thresholds at end of study (83.0 (77.4)g
(SD) allodynia pain scores between the two groups at vs. 85.8 (68.9)g) with no change in pain levels (7.4
baseline(5.4(2.7)vs.5.0(3.4)).Attheendoftreatment, (2.1) and 7.2 (2.2)). In the sativex group, the threshold
themeanreductionofdynamicallodyniawas20%inthe levels increased from 68.8 (47.7)g to 86.2 (73.2)g but
sativexgroup,and5%intheplacebogroup,withanesti- not significantly compared to the placebo group
mated mean treatment difference of (cid:2)0.82 (p=0.042; (p=0.14). Despite this increase of applied punctate
95% CI: (cid:2)1.6, (cid:2)0.03)) in favour of sativex. NNT for pressure there was a notable decrease in the allodynia
30% reduction in the allodynia score was 9.2 and for pain scores (baseline: 7.3 (1.7) vs. end of treatment: 6.2
50% reduction 7.5. (2.6)). The estimated treatment difference of (cid:2)0.87 was
in favour of sativex (p=0.021; 95% CI: (cid:2)1.62, (cid:2)0.13),
3.3.2. Punctate allodynia giving an NNT (30%) of 5.9 and NNT (50%) of 13.4.
At baseline, all randomised patients except one on Inspectionofpunctateallodyniadatarevealedthatin
sativex showed punctate allodynia with clearly reduced some cases the pressure applied with the algometer to
thresholds in the affected area vs. contralateral control the allodynic site had changed considerably between
Table3
Summaryoftheresultsofthesecondaryefficacyend-points(ITTanalysis)
Secondaryoutcomes Sativex Placebo Estimatedmeandifference(95%CI)a p-Value
NPScompositescore (cid:2)10.07 (cid:2)2.04 (cid:2)8.03((cid:2)13.83,(cid:2)2.23) 0.007
SleepdisturbanceNRS (cid:2)0.79 (cid:2)0.36 (cid:2)0.43((cid:2)0.67,(cid:2)0.19) 0.001
PainDisabilityIndex(PDI) (cid:2)5.61 0.24 (cid:2)5.85((cid:2)9.62,(cid:2)2.09) 0.003
DynamicallodyniaNRS (cid:2)1.18 (cid:2)0.37 (cid:2)0.82((cid:2)1.60,(cid:2)0.03) 0.042
PunctateallodyniaNRS (cid:2)1.09 (cid:2)0.21 (cid:2)0.87((cid:2)1.62,(cid:2)0.13) 0.021
GHQ-12 (cid:2)3.09 (cid:2)2.34 (cid:2)0.75((cid:2)2.84,1.35) 0.483
PGIC(allneuropathicpain) 51.61 19.35 32.26(16.40,48.12) <0.001
PGIC(painatallodynicsite) 46.77 17.74 29.03(13.79,44.67) 0.001
a Alltreatmentcomparisonsinfavourofsativex.
)IC
%59(
serocS
peelS
naeM
detsujdA
T.J.Nurmikkoetal./Pain133(2007)210–220 215
Sativex
Placebo
**
* ** **
* P>0.05
** P<0.01
//
Baseline End of Treatment
Fig.3. Reductionissleepdisturbancescoresinthetwogroupsduring
thetrial.Fordetails,seetext,andlegendforFig.2.
216 T.J.Nurmikkoetal./Pain133(2007)210–220
pre-treatment and post-treatment. When a sensitivity both treatment groups, with no tendency to increasing
analysiswascarriedoutinpatientsinwhomtheinvesti- dose over the duration of the study. The number of
gatorsappliedasimilardegreeofforce(<5%greater)to sprays used daily in the placebo group was higher than
the allodynic area on the second testing occasion (44 in the sativex group (Table 4). Over the study period,
patients on sativex and 45 on placebo), there was a sig- patients randomised to sativex used a mean (SD) of
nificantly larger reduction of allodynia pain in the sati- 10.9 (6.8) sprays daily compared with 19.0 (8.3) by
vex group than the placebo group leading to a patients on placebo.
treatment difference of (cid:2)0.94 (p=0.046; 95% CI:
(cid:2)1.85, (cid:2)0.02) in line with the ITT analysis. 3.5. Adverse events and withdrawals
Whenallsubjectswereanalysedtogether,therewasa
strong correlation between the intensity of punctate Fifty-seven (91%) patients in the sativex group expe-
allodynia, dynamic allodynia and spontaneous pain at riencedatleastoneadverseevent(AE)duringthecourse
baseline and end of study, with similar strong correla- ofthestudycomparedwith48(77%)patientsinthepla-
tions between the three parameters for change in scores cebo group. The most frequent AEs were central ner-
(punctate allodynia vs. dynamic allodynia, r=0.526, vous system related or gastrointestinal. Most were
p<0.001; punctate allodynia vs. pain r=0.369; observed at onset of treatment, and in the majority
p<0.001; dynamic allodynia vs. pain, r=0.436, described asmild.However, 6(10%)patientson sativex
p<0.001). Inspection of sativex and placebo groups reported several gastrointestinal AEs (nausea, vomiting
separately showed that similar significant correlations diarrhoea,constipation)withnoneonplaceboreporting
were present, except for change in dynamic allodynia the same. Severe symptoms suggesting involvement of
in the placebo group (r=0.065, p=0.61). the nervous system were reported with sativex in 7
Resultsofthesecondaryefficacy end-pointsaresum- (11%) and placebo 5 (8%) cases. All reported gastroin-
marised in Table 3. Thirty-two (51.6%) patients taking testinalAEscombinedirrespectiveoftheirseveritywere
sativex compared to 12 (19.3%) taking placebo consid- morecommoninthesativexgroup(31/63(49%)thanin
ered their primary condition to be very much, much or the placebo group (20/62 (32%), p=0.003, Fisher’s
minimally improved (p<0.001, Fisher’s exact test). exact test), whereas the nervous system AEs (33/63 vs.
Theoddsratioforachievingabetterresponseonsativex 23/62,p>0.10)werenot.Onecaseofseverepsychiatric
thanplacebo,calculatedfromalogisticregressionofthe AE was recorded on both groups (with sativex, emo-
data, was 3.55 (95% CI: (cid:2)7.61, (cid:2)1.72) in favour of sat- tionalstressassociatedwithparanoidthinkingandwith
ivex. There was no difference between groups in the placebo, confusion) and 6 further mild-to-moderate
GHQ-12 score. onesinthesativexgroupasopposedto3intheplacebo
group;theseweremainlymoodrelated.AEsseenin3or
3.4. Dosing pattern more subjects are shown in Table 5 for all AEs and for
those considered possibly related to treatment.
The mean (SD) number of sprays taken during the In the sativex group, 11 (18%)patientswithdrew due
first week of dose titration for sativex and placebo was to an AE compared with 2 (3%) in the placebo group.
7.3 (3.5) and 10.9 (3.9), respectively. From the second There was one transient ischaemic attack in the sativex
week onwards, the dose frequency remained stable in group rated as a serious adverse event (SAE) and
Table4
Summaryofexposuretostudymedicine(numberofspraysperdaybasedonpatientdiaryentries)
Sativex(N=63) Numberofpatients Placebo(N=62) Numberofpatients
remaining remaining
Week1 Mean(SD) 7.31(3.54) 62 10.94(3.90) 62
Median(range) 6.64(1.3–14.7) 11.14(3.0–21.3)
Week2 Mean(SD) 12.46(8.07) 58 20.08(9.79) 61
Median(range) 10.86(1.6–42.7) 19.71(2.3–47.9)
Week3 Mean(SD) 13.32(8.30) 55 21.10(10.79) 60
Median(range) 11.43(1.7–37.4) 20.07(1.7–48.0)
Week4 Mean(SD) 12.86(8.63) 53 22.23(11.51) 57
Median(range) 10.86(2.0–39.0) 20.43(1.7–48.1)
Week5 Mean(SD) 13.63(8.65) 48 22.26(11.68) 54
Median(range) 12.64(1.1–37.7) 19.93(2.9–50.6)
Overall Mean(SD) 10.89(6.81) 19.02(8.32)
Median(range) 9.81(1.3–31.4) 17.91(2.4–41.5)
T.J.Nurmikkoetal./Pain133(2007)210–220 217
Table5
Treatmentemergentadverseevents(AEs)experiencedby3ormoresubjects((cid:3)5%)receivingsativexcomparedwithplaceboandthe%ofsubject
whowithdrewduetotheseAEs
Adverseevent Number(%)ofpatientsexperiencingAEs Number(%)ofpatientswhowithdrewduetoAE
Sativex(N=63) Placebo(N=62) Sativex(N=63) Placebo(N=62)
Dizziness 18(28.6) 9(14.5) 2(3.2) 0
Nausea 14(22.2) 7(11.3) 1(1.6) 0
Fatigue 13(20.6) 5(8.1) 0 0
Drymouth 11(17.5) 3(4.8) 0 0
Vomiting 8(12.7) 3(4.8) 2(3.2) 0
Feelingdrunk 6(9.5) 1(1.6) 1(1.6) 0
Headache 6(9.5) 9(14.5) 0 0
Diarrhoea 4(6.3) 0 2(3.2) 0
Nasopharyngitis 4(6.3) 2(3.2) 0 0
Anorexia 4(6.3) 0 1(1.6) 0
Somnolence 4(6.3) 1(1.6) 0 1(1.6)
Abdominalpainupper 3(4.8) 1(1.6) 0 0
Disturbanceinattention 3(4.8) 0 0 0
Memoryimpairment 3(4.8) 0 0 0
considered unrelated to study treatment. Oral discom- to that used in the randomisation phase. Patients were
fort, other than dryness of mouth, occurred in 8 (13%) reviewed initially at 4 weeks thereafter every 8 weeks.
patients taking sativex and 11 (18%) taking placebo The duration of participation in the extension trial
andwasusuallyreportedasmild.Onepatientonsativex ranged from 1 to 871 days. By study closure, 56 (63%)
had transient mucosal ulcerations but leukoplakia was patientshadbeenwithdrawn;18patientsduetoadverse
not observed. No significant haematological or bio- effects,16duetolackofefficacy,15duetowithdrawalof
chemical abnormalities were encountered in laboratory consent,7forotherreasons.Themean(SD)durationof
parameters. the participation of withdrawn patients was 135 (147)
The Brief Repeatable Battery of Neuropsychological days. An LOCF analysis involving 76 patients carried
Tests (BRB-N)was givento85patients (43randomised out at 52 weeks demonstrated a mean decrease of pain
to sativex and 42 to placebo). No difference was seen NRSfromthebaselineof7.3(1.4)to5.9(2.4),i.e.,similar
betweengroupsassessedforcognitivefunctionwiththis tothatseenintherandomisedtrial.Thedailynumberof
methodatthebeginningandendoftreatment(Table6). spraysdidnotincreaseappreciablyduringthisperiod(N
Intoxication scores (SD) remained low throughout (SD)10.2(6.0)attheendofthere-titrationvs.12.2(7.6)
the study, peaking after the self-titration week at 8.0 at52weeks).Twoepisodesofseriousadverseeffectswere
(15.4) for sativex and 3.0 (7.9) for placebo on a 0–100 reported (urticaria with eyelid oedema and an event of
scale, respectively. Five patients on sativex and 2 somnolence, dysarthria and weakness) both leading to
patients on placebo scored more than 40/100 during withdrawalofthepatientinquestionfromthestudy.
the maintenance period.
4. Discussion
3.6. Long-term use of sativex
Thisstudydemonstratesthatsativexiseffectiveinthe
At the end of their 5-week trial period, each patient reliefofperipheralneuropathicpainwhengiveninaddi-
was offered the chance to enter an open-label extension tion to existing medication. Greater than 30% improve-
study.Ofthe125subjectseligible,atotal89(71%)ofthe ment in pain intensity, generally considered as clinically
patients accepted the offer. They subsequently under- meaningful [9], was reported by 26% of subjects receiv-
wentre-titrationofsativexfromzero,inawayidentical ing sativex, compared with 15% of patients taking
Table6
PsychomotorfunctionduringthetrialshownasadjustedmeanchangefrombaselineintheBRB-Nforeachtreatmentgroup
Test Sativex N Placebo N Difference p-Value
Selectivereminding 0.55 43 0.52 42 0.02 0.92
10/36Spatialrecall 0.85 43 0.31 42 0.53 0.21
Symboldigitmodalities 1.48 43 3.63 42 (cid:2)2.15 0.16
Pacedserialaddition 7.67 33 6.38 34 1.28 0.66
Wordlistgeneration 2.35 42 2.44 42 (cid:2)0.08 0.96
Nodifferencebetweengroups(positivedifferencedenotesbetterfunctiononsativexandnegativeonplacebo).
218 T.J.Nurmikkoetal./Pain133(2007)210–220
placebo. At recruitment, all our patients were either shows adequate sensitivity to change in longitudinal
non-responders to several conventional neuropathic studies in manifest depression [11]. The role of the
analgesics, or were in severe pain despite taking appro- endocannabinoid system in the regulation of anxiety
priate therapy. Considering the refractory nature of and mood disorders still remains unclear, and both
their pain, and that patients remained on their existing CB1 agonists and antagonists have been shown to pos-
analgesia,theimprovementoftheongoingpaininthose sess either anxiolytic or anxiogenic effects as well as
on the active drug is encouraging. Further evidence for variable effects on mood [38]. It is possible that
the efficacy of sativex comes from improvement in GHQ-12 cannot detect modest changes in a population
mechanical dynamic and punctate allodynia pain, sleep such as ours scoring just above the mean of the general
and disability demonstrated in this study. Reduction in population [24]. Alternatively, the above paradoxical
systematically measured mechanical allodynia is not effects of THC, or the ability of CBD to block some
commonly reported in controlled trials on neuropathic of the psychomimetic effects of THC, may explain
pain [17] and usually only seen in single dose studies the lack of change in this measure.
or following other than oral administration, and failure Theself-titrationscheduleusedinthisstudywascho-
iscommon.[3,21,23,29,34–36].Becausetodatethereare sen for severalreasons. Previous studies[6,26]indicated
noreliabledataconvertingreductioninallodyniascores that individual subjects have a variable threshold to the
to clinically meaningful improvement, the NNT values knownpharmacodynamiceffectsofsativex.Aself-titra-
presented should be interpreted with caution. tion regimen permitted individual patients to optimise
In comparison with pain relief reported from other their dose on the basis of their own efficacy and tolera-
cannabis-related clinical trials, sativex in our group of bilityresponse.Bothexperimentalandhumanvolunteer
patients demonstrated a greater difference over placebo studies suggest that tolerance to some of the side effects
(0.96,95%CI(cid:2)1.59,(cid:2)0.32)thaninpatientswithplexus of cannabis occurs within days of its repeated adminis-
avulsion (treatment difference (cid:2)0.58, 95% CI (cid:2)0.98, tration[14,18,22].Aself-titrationregimenallowsforthis
(cid:2)0.18) but somewhat less than in patients with central to occur, further optimising the therapeutic response.
pain due to MS ((cid:2)1.25; 95% CI (cid:2)2.11, 0.39) [6,26]. There appears to be substantial between-patient vari-
The treatment difference reported for dronabinol in ability in the pharmacokinetics of THC and other can-
MS patients deprived of concomitant analgesic medica- nabinoids [13,14] and in such circumstances the
tionwas0.6(95%CI(cid:2)1.8,0)whilethatforsmokedcan- implementationofafixed-doseregimenislikelytoyield
nabisinpainfulHIVneuropathywasapproximatelythe suboptimal results.
same as in the present study (as extrapolated from the Themeannumberofspraystakendailybythesativex
reported median 18% treatment difference in pain relief group remained stable during the course of the study
frommeanbaselinescoresof53and54/100)[1,30].Dif- despite patients having the freedom to determine their
ferences in patient populations, numbers of withdraw- owndosing,indicatingthattolerancedidnotdevelopat
als, concomitant medications, trial designs and trial leastoverthe4-weekstabletreatmentperiodofthisstudy.
durationsprobablyexplainagreatdealofthesevarying Thedosetitrationregimenusedwasusuallysuccessfulin
results.Interestingly,thetwoothercannabinoidtrialsin providing the optimal therapeutic level for individual
whichevokedpainwasassessed,albeitinalimitedfash- patients.Thisconclusionisendorsedbytheobservation
ion, also report some benefit in line with the present thatthosepatientswhotookpartintheopen-labelexten-
study [1,30]. sion study did not increase the number of daily sprays
Our reason for maintaining existing analgesia was during the first 52 weeks of open-label treatment while
based on both ethical and clinical considerations. A apparentlymaintainingtheinitialanalgesiceffect.
number of treatments that have shown efficacy in While the therapeutic effects of cannabis have often
peripheral neuropathic pain are in widespread use in been attributed to THC, the second major constituent
accordance with existing guidelines [2]. Depriving a of the trial medication, CBD has been shown to have
patient from such therapies during a placebo-controlled effects which may be additive to those of THC in pain
trial could not be ethically justified. Clinical practice is relief in animal models, and also to have the potential
also moving toward combination therapies due to the to ameliorate some of the psychoactive effects of THC
realisation that in chronic neuropathic pain multiple [27]. This interaction between the two components
mechanisms are the norm [12,39]. may permit subjects to tolerate mean daily doses of
The lack of GHQ-12 to show any change during the more than 27mg THC. This dose is in excess of those
present study is in line with virtually all other cannab- used in other controlled studies of THC, and may
inoid trials in which the psychosocial domain was account for the observed efficacy [14].
explored, irrespective of the measure used (GHQ-30, The adverse events reported by the patients were
[40]; GHQ-28, [33]; SF-36, [30]; GHQ-12, [6]; HADS, mostly gastrointestinal, central nervous system related
[26]; POMS, [1]). GHQ-12 is a well-validated measure or topical. While reported gastrointestinal AEs were
of anxiety, depression and social dysfunction [37] and morecommoninthesativexgroup,centralnervoussys-
T.J.Nurmikkoetal./Pain133(2007)210–220 219
temAEswerenot;and,importantly,objectivemeasure- [2] Attal N, Cruccu G, Haanpa¨a¨ M, Hansson P, Jensen TS,
ment of psychomotor performance did not vary across Nurmikko T, et al. EFNS guidelines on pharmacological treat-
mentofneuropathicpain.EurJNeurol2006;11:1153–69.
the two groups. In general, the number of patients who
[3] Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D.
withdrewissimilartothosereportedinwell-knownlarge
Systemic lidocaine in pain due to peripheral nerve injury and
trialsofotherdrugsusedinneuropathicpain[4,25].That predictorsofresponse.Neurology2004;62:218–25.
PCIGscoresfavouredsativexoverplacebosuggeststhat [4] BackonjaMA,BeydounA,EdwardsKR,SchwartzSL,Fonseca
subjective pain relief, reduced disability and improved V, Hes M, et al. Gabapentin for the symptomatic treatment of
painfulneuropathyinpatientswithdiabetesmellitus:arandom-
sleepoverrodethenegativeimpactofAEs.
izedcontrolledtrial.JAMA1998;280:1831–6.
There was no formal assessment of whether unblin-
[5] BanksMH.ValidationoftheGeneralHealthQuestionnaireina
ding might have taken place. The psychotrophic effects youngcommunitysample.PsycholMed1983;13:349–53.
of cannabis are well known to the public, and 20% of [6] Berman JS, Symonds C, Birch R. Efficacy of cannabis based
the participants in the present trial had previous expo- medicinal extracts for relief of central neuropathic pain from
sure to cannabis. A post-hoc analysis found that previ- brachialplexusavulsion:resultsofarandomizedcontrolledtrial.
Pain2004;112:299–306.
ous use of cannabis was not predictive of the change
[7] Bever Jr CT, Grattan L, Panitch PH, Johnson KP. The Brief
in mean pain scores. Classical psychotrophic effects of
Repeatable Battery of Neuropsychological Tests for Multiple
cannabis were reported by relatively few patients. The Sclerosis:apreliminaryserialstudy.MultScler1995;1:165–9.
intoxicationscoresweremarginallyhigherinthesativex [8] Costa B, Giagnoni G, Franke C, Trovate AE, Colleani M.
group, and psychometric tests (BRB-N) remained VanilloidTRPV1receptormediatestheantihyperalgesiceffectof
thenonpsychoactivecannabinoid,cannabidiol,inaratmodelof
unchanged during the trial. It is therefore unlikely that
acuteinflammation.BrJPharmacol2004;143:247–50.
asignificantnumberofthoseonsativexwouldhavecor-
[9] Farrar JT, Young JP, La Moreaux L, Werth JL, Poole RM.
rectly guessed they were on active medication unless Clinicalimportanceofchangesinchronicpainintensitymeasured
theydeliberatelyoverdosed.Fromreturnedtrialmedica- onan11-pointnumericalpainratingscale.Pain2000;94:149–58.
tionitwasconcludedthatsuchpracticedidnottakeplace. [10] GalerBS,JensenMP.Developmentandpreliminaryvalidationof
apainmeasurespecifictoneuropathicpain:theNeuropathicPain
Patients taking placebo may have concluded that they
Scale.Neurology1997;48:28–33.
weretakinginactivesubstance,giventhattheyusedarel-
[11] Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M,
ativelyhighnumberofsprays.However,themajorityof
GurejeO,et al.ThevalidityoftwoversionsoftheGHQinthe
patientstooklessthanthehighestallowabledosage.Also, WHOstudyofmentalillnessingeneralhealthcare.PsycholMed
only5(8%)oftheplacebogroupwithdrewforlackofeffi- 1997;27:191–7.
cacy,suggestingthatnosignificantunblindingtookplace. [12] GilronI,BaileyJM,TuD,HolderR,WeaverDF,HoulderRL.
Morphine,gabapentin,ortheircombinationforneuropathicpain.
We conclude that the results from this study indicate
NEnglJMed2005;352:1324–34.
that sativex has a positive broad spectrum therapeutic
[13] Guy GW, Flint ME. A single centre, placebo-controlled, four
effectinneuropathicpain,whenusedinadditiontoexist- period, crossover, tolerability study assessing pharmacokinetic
inganalgesicmedication.Theemergenceofahighlystan- effects, pharmacokinetic characteristics and cognitive profiles of
dardised,uniformpreparationofTHC:CBDshouldallow as single dose of three formulations of cannabis based medicine
extracts (CBMEs) plus a two period tolerability study compar-
forfurtherstudieswhichbetterdefinetheroleforcannab-
ing pharmacodynamic effects and pharmacokinetic characteris-
inoidsinthetreatmentofneuropathicpainsyndromes.
tics of a single dose of a cannabis based medicine extract given
via two administration routes. J Cannab Ther 2003;3:35–77.
[14] Guy GW, Robson P. A Phase I, a double blind, three-way
Acknowledgements
crossoverstudytoassessthepharmacokineticprofileofcannabis
based medicine extract (CBME) administered sublingually in
GW Pharma acted as the sponsor of the study, pro- variant cannabinoid ratios in normal healthy male volunteers. J
vided the medication, participated in the study design, CannabTher2003;3:121–52.
co-ordinated the study between centres and carried out [15] HerzbergU,EliavE,BennettGJ,KopinIJ.Theanalgesiceffects
of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid
thefirstsetofanalyses.Theanalyseswereverifiedbyan
agonist, in a rat model of neuropathic pain. Neurosci Lett
independent statistician. The principal investigator had
1997;221:157–60.
fullaccesstoallthedataandcarriedoutfurtherconfirma- [16] IskedijanM,BerezaB,GordonA,PiwkoC,EinarsonTR.Meta-
toryanalyses.Allauthorscontributedtothestudydesign, analysis of cannabis based treatments for neuropathic and
collectionofthedataandinterpretationoftheresults.The multiplesclerosispain.CurrMedResOpin2007;23:17–24.
[17] Jensen TS. Anticonvulsants in neuropathic pain: rationale and
editorialcontentofthispaperisoftheauthors,asisthe
clinicalevidence.EurJPain2002;6(SupplA):618.
finaldecisiontosubmitforpublication.
[18] Jones RT. Cardiovascular system effects of marijuana. J Clin
Pharmacol2002;42:58S–63S.
[19] Karst M, Salim K, Burstein S, Conrad I, Hog C, Schneider U.
References Analgesic effect of the synthetic cannabinoid CT-3 on chronic
neuropathicpain.JAMA2003;290:1757–62.
[20] MatsudaLA,LolaitSJ,BrownsteinMJ,YoungAC,BonnerTI.
[1] Abrams DI, Jay CA, Shade SB, Vizoso RN, Reda H, Press S,
Structure of cannabinoid receptor and functional expression of
et al.CannabisinpainfulHIV-associatedsensoryneuropathy.A
theclonedcDNA.Nature1990;346:561–4.
randomisedplacebo-controlledtrial.Neurology2007;68:515–21.
220 T.J.Nurmikkoetal./Pain133(2007)210–220
[21] MeierT,WassnerG,FaustM,KuntznerT,OchsnerF,Hueppe [31] Tait RC, Chibnall JT, Krause S. The Pain Disability Index:
M,et al.Efficacyoflidocainepatch5%inthetreatmentoffocal psychometricproperties.Pain1990;40:171–82.
peripheral neuropathic pain syndromes: a randomized, double- [32] VarvelSA,WileyJL,YangR,BridgenDT,LomgK,Lichtman
blind,placebo-controlledtrial.Pain2003;106:151–8. AH,et al.InteractionsbetweenTHCandcannabidiolinmouse
[22] NahasGG,SchwartzIW,AdamecJM,MangerWM.Tolerance models of cannabinoid activity. Psychopharmacology
of delta 9 THCin the spontaneouslyhypertensive rat.Proc Soc 2006;186:226–34.
ExpBiolMed1973;142:58–60. [33] Wade DT, Makela P, Robson P, House H, Bateman C. Do
[23] NikolasjenL,GotrupHKristensenAG,JensenTS.Memantine cannabis-basedmedicinalextractshavegeneralorspecificeffects
(aN-methyl-D-aspartatereceptorantagonist)inthetreatmentof in multiple sclerosis? A double-blind, randomised, placebo-
neuropathic pain after amputation or surgery: a randomized, controlledstudyon160patients.MultScler2004;10:434–41.
double-blind,cross-overstudy.AnesthAnalg2000;91:960–6. [34] WallaceM,BraunJ,SchultersG.Postdeliveryofalfentanil and
[24] Pevalin DJ. Multiple applications of the GHQ-12 in a general ketaminehasnoeffectonintradermalcapsaicininducedpainand
populationsample:aninvestigationoflong-termretesteffects.Soc hyperalgesia.ClinJPain2002;18:373–9.
PsychiatryPsychiatrEpidemiol2000;35:508–12. [35] Wallace MS, Magnusson S, Ridgeway B. Efficacy of oral
[25] Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a mexiletine for neuropathic pain: a double-blind, placebo-con-
randomised, double-blind, placebo-controlled study. Pain trolled, cross-over study. Reg Anesth Pain Med
2001;94:215–24. 2000;25:459–67.
[26] Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized [36] WallaceMS,RowbothamMC,KatzNP,DworkinDH,Dotson
ControlledTrialofCannabisBasedMedicineinCentralNeuro- RM, Galer BS, et al. A randomized, double-blind, placebo-
pathicPainduetoMultipleSclerosis.Neurology2005;65:812–9. controlled trial of glycine antagonist in neuropathic pain. Neu-
[27] Russo EB, McPartland JM. Cannabis is more than simply rology2002;59:1694–700.
Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) [37] Werneke U, Goldberg DP, Yalsin I, Ustun BT. The stability of
2003;165:431–2. thefactorstructureoftheGeneralHealthQuestionnaire.Psychol
[28] SagarDR,KellyS,MillnsPJ,O’ShaughnesseyCT,KendallDA, Med2000;30:823–9.
ChapmanV.InhibitoryeffectsofCB andCB receptoragonists [38] Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid
1 2
on responses of DRG neurons and dorsal horn neurons in CB1receptorsinmoodandanxietydisorders.BehavPharmacol
neuropathicrats.EurJNeurosci2005;22:371–9. 2005;16:315–31.
[29] Serpell MG. Neuropathic Pain Study Group. Gabapentin in [39] WoolfCJ.Dissectingoutmechanismsresponsibleforperipheral
neuropathic pain syndrome: a double-blind, placebo-controlled neuropathicpain:implicationsfordiagnosisandtherapy.LifeSci
trial.Pain2002;99:557–66. 2004;74:2605–10.
[30] Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid [40] ZajisecJ,FoxP,SandersH,WrightD,VickeryJ,NunnA,et al.
dronabinolreducecentralpaininmultiplesclerosis?Randomised Cannabinoids for treatment of spasticity and other symptoms
double blind placebo controlled crossover trial. Br Med J relatedtomultiplesclerosis(CAMSstudy):multicentrerandom-
2004;329:25–38. isedplacebo-controlledtrial.Lancet2003;363:1517–26.
